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Prevalence of torque teno virus in healthy individuals and 
those infected with hepatitis C virus living in Yazd, Iran 
 
Abstract 
Background: Torque teno virus (TTV) is a non-enveloped DNA virus that its role as a 
helper or causative agent in hepatitis is still unclear. TTV prevalence varies in different 
regions of the world. This study aimed to determine the prevalence of TTV in healthy 
individuals and those infected with hepatitis C virus (HCV) living in Yazd city, Iran. 
Methods: In this case-control study, 50 healthy subjects and 68 HCV-positive individuals 
who referred to Yazd hospitals participated in this study. TTV DNA in serum samples 
were detected by nested polymerase chain reaction (PCR) using specific primers of 5΄-
UTR and N22 regions. The genotypes of HCV and TTV were determined by sequencing 
method. 
Results: TTV-DNA was detected in 2 out of 50 (4℅) healthy individuals and in 4 out of 68 
(5.8℅) HCV-positive persons. There was not a significant correlation between the 
prevalence of TTV and HCV infection. The most common TTV genotypes among HCV-
positive individuals were 3, 17 and 13, respectively. There was not a significant 
association obtained between HCV genotypes and TTV genotypes. 
Conclusion: The prevalence of TTV in Yazd province was low compared with the other 
areas of Iran. The prevalence of TTV in HCV infected people was not significantly higher 
than its rate in uninfected individuals. 
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Torque teno virus or transfusion transmitted virus (TTV) is a non-enveloped virus 
with single stranded circular DNA genome that is currently classified in the 
Alphatorquevirus genus and the family of Anelloviridae (1). TTV was first isolated in 
1997 from serum of a Japanese patient with non A-G hepatitis who had history of blood 
transfusion (2). Unlike other DNA viruses, TTV has an extremely wide genomic diversity, 
so that five main clades and more than 35 genotypes have already been detected. 
Unexpected high mutation rate in TTV DNA could be due to recombination, intragenomic 
rearrangement or the presence of hypervariable regions in ORF1 (3). In the past, blood 
transfusion was considered as the only transmission route of TTV, but today it is suspected 
to be transmitted through intravenous drugs, sexual, maternal and fecal-oral routes (4). The 
prevalence of TTV ranged from 1 to 34℅ among healthy people in developed countries 
and from 40 to 70℅ in the developing countries (5) based on molecular tests. The 
seroprevalence of TTV among adults and children 2–4 years is reported 42℅ and 43℅, 
respectively. TTV13 species-specific IgG was predominated in adults, whereas TTV13 
IgG was predominated in children (6). Some researchers have observed a high 
seroprevalence of TTV up to 98.6% in hepatitis patients with unknown etiology as well as 
in blood donors (7).  
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Previous studies have shown that torque teno virus is 
hepatotropic and replicates in liver. The titer of TTV genome 
has been reported 10-100-fold higher in liver tissue than in 
serum. TTV DNA is detected in 47℅ of patients suffering 
from fulminant hepatic failure and in 46% of patients with 
chronic hepatitis of unknown etiology (8). Nevertheless, the 
role of TTV in acute and chronic liver diseases remains 
unclear and controversial (9).  
Some studies have evaluated the association between 
TTV, hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections (4, 10, 11). Researchers have found the high TTV 
viral load as a significant risk factor for hepatocellular 
carcinoma (HCC) in people with HCV. HCV/TTV co-
infection can result in a higher histological grade score 
compared to HCV infection without TTV (12). 
Variations in nucleotide sequence of TTV genotypes 
have led to create different genotypes. In the majority of 
studies, TTV genotypes have been determined using N22 
region of viral genome. Recent reports have used 
untranslated region (UTR) of viral genome for genotyping 
(13). The UTR region is conserved and contains sequences 
with more than 90% identity among all genotypes. UTR 
primers can detect more TTV genotypes in comparison with 
N22 primers. Phylogenetic analysis performed on the UTR 
region is more accurate (4).  
In recent years, researchers have focused on the 
prevalence and genotyping of TTV in healthy individuals 
and HCV infected peoples. Data published on circulating 
TTV genotypes in different areas of Iran are low; therefore, 
the present study aimed to estimate the prevalence of TTV in 
HCV infected and uninfected people and determine TTV 
genotypes in HCV-positive peoples living in Yazd, Iran.  
 
 
Methods 
Study population: In this case-control study, 68 people with 
HCV infection and 50 healthy individuals who referred to 
hospitals in Yazd city participated. Individuals with a 
positive-PCR result for HCV were included in the study as 
case while people with negative-HCV-PCR test were 
considered as control (sex and age-matched). Subjects with 
liver disorder, autoimmune diseases, cancer, HBs-Ag, HIV-
Ab and HCV-Ab were excluded from the control group. 
Three milliliters of blood sample were collected from the 
subjects. Serum was separated and cryopreserved at -70°C 
until analysis time. Demographic data were collected by a 
questionnaire.  This study was approved by the Ethics 
Committee of Shahid Sadoughi University of Medical 
Sciences-Yazd (Ethical code: IR.SSU. 
SPH.REC.1391.181964. All subjects completed the 
informed consent forms. 
TTV detection through PCR and genotype determination 
via sequencing: Viral DNA was extracted from sera using 
the High Pure Viral Nucleic Acid kit (Roche Diagnostics, 
Mannheim, Germany) according to manufacturer's protocol. 
Then, nested polymerase chain reaction (Nested PCR) was 
performed using primers, which replicated 5’-UTR or N22 
region of TTV genome (table 1).  
 
Table 1. Primer sequences for detection of torque teno virus 
Primer  Region Primer Sequence 
NG 054 5’-UTR 5΄- TTT GCT ACG TCA CTA ACC AC -3΄ 
NG1471 5’-UTR 5΄-GCC AGT CCC GAG CCC GAA TTG CC-3΄ 
NG1321 5’-UTR 5΄-AGC CCG AAT TGC CCC TTG AC -3΄ 
NG059 N22 5΄-ACA GAC AGA GGA GAA GGC AAC ATG-3΄ 
NG061 N22 5΄-GGC AAC ATG YTR TGG ATA GAC TGG-3΄ 
NG063 N22 5΄-CTG GCA TTT TAC CAT TTC CAA AGT T-3΄ 
 
The reaction mixture of first round of nested PCR test for 
TTV-N22 region contained 10 μL of template DNA, 0.5 μL 
primer NG059 (10pM stock), 0.5 μL primer NG061(10pM 
stock), 12.5 μL of the master mix (Sinaclon, Tehran, Iran) 
and  1.5 μL of DEPC water. The second round of reaction 
was performed using 10 μL of the first product, 0.5 μL of 
primer NG059 (10pM stock), 0.5 μL primer NG063 (10pM 
stock) 12.5 μL of the master mix (Cinnagen, Tehran, Iran) 
and 1.5 μL of DEPC water. PCR amplification was 
performed with an initial denaturation at 94 °C for 7 min 
followed by 40 (for the first round) or 35 (for the second 
round) cycles of 30 sec at 94 °C, 45 sec at 60 °C, and 1 min 
at 72 °C, with a final extension at 72 °C for 5 min. The PCR 
products were run on 2% agarose gel by electrophoresis, 
stained with DNA safe stain (Cinnagen, Tehran, Iran), and 
visualized using a gel documentation system. The 
amplification fragment of the second step of PCR was 271 
bp.  
The nested PCR reaction for TTV-5’UTR region was 
carried out with same volumes and reaction contents noted 
for the N22. NG054 and NG1471 primers were used in the 
first step of PCR, and the second round was performed using 
NG054 and NG1321 primers. The amplification was carried 
using temperature conditions as follows: initial denaturation 
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at 94 °C for 5 min, 35 (for the first round) or 25 (for the second 
round) cycles of 94°C at 45 sec, 60°C at 45sec, 72°C at 45 
sec with and final extension at 72°C for 5 min. The amplification 
fragment of the second step of PCR was 220bp. Nested PCR 
products of TTV-N22 and TTV-5’UTR regions purified and 
sequenced using a DNA sequencing system and BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems 
Foster City, CA) according to the manufacturer’s protocols. 
TTV genotypes were determined by the alignment of PCR 
product sequences with the sequences of TTV genotypes, 
which were obtained from GenBank. Phylogenetic analysis 
was performed based on the 5' untranslated region of TTV 
genome reference sequences by MEGA7 software and 
neighbor-joining (NJ) method. Phylogenetic tree was 
constructed with 500 bootstrap repeats. Statistical analysis 
was carried out using Student’s t-test, and chi-square test by 
SPSS software Version 22. A pvalue less than 0.05 was 
considered significant. 
 
 
Results 
Table 2 shows the subjects' characteristics and the result 
of the laboratory tests. Serum samples of 118 participants 
(74 men and 44 women) including 68 individuals with HCV 
infection and 50 healthy subjects were screened by PCR test 
for finding the TTV genome using specific primers for 5’-
UTR and N22 regions.  
TTV-DNA was detected in 4 out of 68 (5.8%) HCV-
positive individuals and in 2 out of 50 (4%) healthy 
individuals (fig 1). 
 
Table 2. Patient’s characteristics and results of laboratory tests 
Characteristic 
Number (%) 
Pvalue 
TTV+ TTV- 
Age group 
(years) 
≤30 4 (7) 53 (93) 
0.846 
30-40 2 (4.2) 46 (95.8) 
40-50 0 9 (100) 
≥50 0 4 (100) 
Sex 
Male 1 (1.4) 73 (98.6) 
0.027 
Female 5 (11.4) 39 (88.6) 
HCV infection 
Positive 5 (7.4) 63 (92.6) 
0.240 
Negative 1 (98) 49 (2) 
Aminotransferases 
ALT 57±25.47 33.5±10.66 0.043 
AST 44±13.79 44.04±21.59 0.996 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Detection of torque teno virus (TTV) by polymerase chain reaction of the 5' untranslated region of genome. Lane 
1 (L), 100 bp DNA ladder; lanes 2 to 4 (S1, S2, S3), positive samples of TTV; lanes 5 (PC) and 6 (NC), positive and negative 
controls, respectively. 
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These data did not show a significant correlation in the 
prevalence of TTV between case and control group (p=0.240). 
ALT in TTV positive subjects was significantly higher than 
those negative for TTV (p=0.043), but AST did not show a 
significant difference between the two groups. Of the 68 
individuals with HCV, 63.2% had genotype 1a and 36.8% 
were identified for genotype 3a. The most frequent HCV 
genotype in TTV-positive subjects was 1a. There was not a 
correlation observed between HCV genotypes and HCV/TTV 
coinfection (p=0.645). Phylogenetic analysis was performed 
(Fig 2) and only three genotypes of TTV were detected in 
HCV-positive persons (table 3). The most common genotypes 
were 3, 17 and 13, respectively. The different TTV genotypes 
were not associated with HCV genotypes (p=0.858).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Phylogenetic tree of TTV constructed by the neighbor-joining method, Based on 5’-UTR sequence. Black 
triangles denote samples under study. 
 
Table 3. Genotype distribution of TTV in people infected with HCV  
 
Result 
TTV result (%) 
P value 
Genotype 3 Genotype17 Genotype 13 Negative 
HCV genotype 
1a 2 (4.7) 2 (4.7) 1 (2.3) 39 (88.3) 
0.858 3a 1 (4) 0 0 24 (96) 
Total - 3 (4.3) 2 (2.9) 1 (1.5) 63 (91.3) 
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Discussion 
TTV was isolated for the first time from a cryptogenic 
hepatitis patient, therefore, assumed that its pathogenicity 
could be associated with hepatitis (14). Some studies have 
significantly reported higher rates of TTV infection in HCV-
positive persons compared with healthy individuals (4, 15, 
16), but the role of TTV as a helper or causative agent in 
hepatitis is still unclear.  
In the present study performed in Yazd, the prevalence of 
TTV-DNA in healthy subjects and HCV infected individuals 
was 4% and 5.5%, respectively. The rate of TTV among the 
healthy population in Yazd is lower than the other reports in 
IRAN. The prevalence of TTV has been estimated to be 
66.9% in Tehran, 23.7% in Ahvaz, 92.5% in Shiraz (4), and 
41% in Isfahan (17). The rate of TTV in the southwest of 
Iran was reported to be low (2.9%) (18) similar to the result 
of the current study.      
In this study, the results did not show a significant 
correlation between the prevalence of TTV and HCV 
infection (P=0.240). The association between TTV and HCV 
is still controversial. Some  researchers  have  found  a  
correlation between these two viruses, while the others  
could  not  show  any  relationship. The prevalence of TTV 
in the USA and European countries has reported about 1%. 
In Pakistan, TTV prevalence was reported 3.6% in HCV 
positive persons and 3.2% in healthy individuals (19). That 
is in range of the current study. In contrast with the result of 
the present study, some studies conducted in Iran have found 
a correlation between the prevalence of TTV and HCV 
infection.  
In a study performed in Jahrom, by Mousavinasab et al., 
18% of the healthy subjects and 66.5% of HCV-positive 
individuals were positive for TTV (16). In the study of 
Kenarkoohi et al., the prevalence of TTV in HCV-positive 
persons living in Shiraz was more than 90% (4). TTV was 
detected in 65% of healthy people and 67.5% of HCV-
infected individuals in east Azerbaijan province (15); 
therefore, similar to our finding, the prevalence of TTV in 
HCV-positive people was not significantly more than the 
HCV-negative subjects.  
Several factors, including geographical distribution of 
population, sample size and the diagnostic methods can 
make the variability in the results of TTV prevalence. The 
primers for detecting of TTV in our study and studies noted 
above were designed for the same region of viral genome 
(5'UTR and N22); therefore, it can be concluded that the 
prevalence of TTV in Yazd province is significantly lower 
than in Jahrom, Shiraz and east Azerbaijan among the HCV-
positive or negative people. There was not any report found 
in the literature review on the TTV prevalence in Yazd.   
TTV is a DNA virus, but unusual genetic variability 
occurs in its genome. The presence of animal carriers of the 
virus and the genetic recombination of viruses among human 
or human with animal may contribute in making diversity in 
TTV genome. Five main clades and more than 35 genotypes 
have already been determined for TTV. In the present study, 
genotypes 3, 17 and 13 were found in HCV-positive group, 
and we did not determine TTV genotypes in the control 
group. Kenarkoohi et al. detected genotypes 1, 3, 17, and 22 
in people infected with HCV and genotype 11 was 
predominant (4).  
In a study conducted in Qatar, the most frequent 
genotypes isolated from HCV-positive individuals were 2, 3, 
5, and 1, respectively (3). Previous studies showed that the 
dominant TTV genotypes worldwide are 1 and 3, while in 
Iran is 2 (4). The result of the present study did not show a 
significant association between HCV and TTV genotypes. 
This finding may be due to the low prevalence of TTV 
among our study population, but the previous studies also 
did not find a correlation between genotypes of these two 
viruses (3).  
Finally, the prevalence of TTV in Yazd province is low 
in comparison with other areas of Iran. The prevalence of 
TTV in HCV-positive individuals is not significantly higher 
than its rate in healthy people. The most common TTV 
genotypes were 3, 17 and 13, respectively. Further studies 
with more sample size are required to confirm these findings 
in Yazd province of Iran. 
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